Figure 1.

IFN-α2b treatment accelerated viral clearance. Confirmed COVID-19 cases were treated either with ARB alone (ARB; 24 patients) or IFN-α2b with or without ARB (IFN; 53 patients). Upper respiratory samples were assessed by PCR for the presence of SARS-CoV-2. Shown is the proportion of patients that had detectable virus as a function of the day of sampling from symptom onset. Empirical survival curves are shown here, while the p-value for treatment effect was assessed using a Cox proportional-hazards model that included age and co-morbidities as covariates.